Image Source: AsiaOne
AIM ImmunoTech Announces First Healthy Subjects Dosed in Phase 1 Intranasal Ampligen Clinical StudyMarks important milestone towards development of Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseasesGlobeNewswireMarch 08, 2021OCALA, Fla., March 08, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has dosed the first healthy subjects in its Phase 1 clinical study on the safety of AIM’s drug Ampligen as a potential intranasal therapy. AIM’s ’s goal is to develop Ampligen as a potential intranasal prophylaxis or early-stage treatment for COVID-19 and other respiratory viral diseases.
Source: AsiaOne